PTCTPTC THERAPEUTICS, INC.vs its industry peers
A metric-by-metric comparison of PTC THERAPEUTICS, INC. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTCTThis | $5.8B#14 | — | — | 3.3x#1 | 114.5%#5 | 288.0%#2 | 50.1%#1 | — | — | — | 32.9%#11 | — |
| MDGL | $11.8B#6 | — | 22.5x#10 | 12.3x#5 | 432.1%#2 | 38.1%#5 | -31.3%#6 | -55.0%#8 | -52.5%#4 | — | 63.2%#10 | — |
| TGTX | $7.2B#13 | 16.5x#1 | 12.4x#4 | 11.7x#4 | 87.3%#6 | 1811.1%#1 | 20.0%#3 | 76.7%#1 | 13.9%#2 | — | 64.3%#9 | — |
| INSM | $21.4B#3 | — | 30.4x#11 | 35.3x#8 | 66.7%#7 | -39.7%#9 | -205.6%#8 | -181.1%#11 | -185.1%#6 | 4#1 | -11.1%#13 | — |
| SRRK | $5.7B#15 | — | 20.8x#8 | — | — | -53.7%#11 | — | -137.0%#9 | -901.6%#7 | — | 29.3%#12 | — |
| APGE | $10.0B#8 | — | — | — | — | -40.5%#10 | — | — | — | — | 260.7%#3 | — |
| PTGX | $8.7B#11 | — | 13.2x#5 | 188.2x#10 | -89.4%#11 | -147.3%#13 | -343.6%#9 | -19.9%#5 | -33.5%#3 | — | 150.2%#5 | — |
| SMMT | $11.1B#7 | — | 17.7x#6 | — | — | -387.8%#14 | — | -171.4%#10 | — | — | -52.4%#15 | — |
| UTHR | $21.9B#2 | 19.1x#2 | 3.7x#1 | 6.9x#2 | 10.6%#9 | 11.7%#6 | 46.9%#2 | 22.6%#3 | — | — | 76.3%#7 | — |
| PRAX | $8.7B#10 | — | 6.2x#2 | — | -100.0%#12 | -65.6%#12 | — | -21.5%#6 | — | — | 512.8%#1 | — |
| ARWR | $12.6B#5 | — | 20.5x#7 | 15.1x#6 | 23258.2%#1 | 99.7%#4 | 11.9%#5 | -0.3%#4 | — | — | 442.3%#2 | — |
| COGT | $7.3B#12 | — | 12.1x#3 | 930.4x#11 | -65.0%#10 | -28.6%#7 | -4235.3%#11 | -54.1%#7 | -81.2%#5 | — | 255.1%#4 | — |
| BBIO | $16.1B#4 | — | — | 32.1x#7 | 126.3%#4 | — | -104.2%#7 | — | — | — | 72.4%#8 | 0.0%#1 |
| CYTK | $9.8B#9 | — | — | 111.8x#9 | 376.6%#3 | -33.2%#8 | -695.4%#10 | — | — | — | 116.3%#6 | — |
| ALNY | $29.2B#1 | 38.1x#3 | 21.6x#9 | 7.9x#3 | 65.2%#8 | 212.8%#3 | 13.5%#4 | 23.2%#2 | 150.5%#1 | — | -47.9%#14 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-08-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice